{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:48:50Z","timestamp":1786546130138,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurol.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:41:57Z","timestamp":1780342917000},"page":"609-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ambulatory introduction of foslevodopa\/foscarbidopa in Parkinson's disease in private practice. Case series of the first 22 patients"],"prefix":"10.1016","volume":"182","author":[{"given":"C.","family":"Bonnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mesnage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jaulent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neurol.2026.04.009_bib0080","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continious subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soilieau","year":"2022","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2026.04.009_bib0085","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mdc3.70060","article-title":"Cognitive and psychiatric adverse effects of foslevodopa\/foscarbidopa in patients with Parkinson's disease","volume":"12","author":"Broh\u00e9e","year":"2025","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"10.1016\/j.neurol.2026.04.009_bib0090","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/mdc3.70249","article-title":"Foslevodopa\/foscarbidopa continuous subcutaneous infusion in Parkinson's disease: real-world short-term data on tolerability, infusion rate adjustments and concomitant medication","volume":"12","author":"Rukavina","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neurol.2026.04.009_bib0095","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson's disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study","volume":"12","author":"Aldred","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurol.2026.04.009_bib0100","first-page":"100239","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: considerations for initiation and maintenance","volume":"10","author":"Fung","year":"2024","journal-title":"Clin Park Relat Disord"},{"issue":"12","key":"10.1016\/j.neurol.2026.04.009_bib0105","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/mdc3.70254","article-title":"Clinical impact of switching from subcutaneous apomorphine to foslevodopa\/foscarbidopa in advanced Parkinson's disease: a real-world observational study (FOSAPO)","volume":"12","author":"Desjardins","year":"2025","journal-title":"Mov Disord Clin Pract"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neurol.2026.04.009_bib0110","doi-asserted-by":"crossref","first-page":"107866","DOI":"10.1016\/j.parkreldis.2025.107866","article-title":"A Delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations","volume":"139","author":"Ory Magne","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.neurol.2026.04.009_bib0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa dose equivalency in Parkinson's disease: updated systematic review and proposals","volume":"38","author":"Jost","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurol.2026.04.009_bib0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2026.04.009_bib0130","series-title":"ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration","year":"1976"},{"issue":"15","key":"10.1016\/j.neurol.2026.04.009_bib0135","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2026.04.009_bib0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression, and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2026.04.009_bib0150","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1877718X251344896","article-title":"Twenty-five-year experience with apomorphine pump in Parkinson's disease: a real-life long-term retrospective tolerance study","volume":"15","author":"Potel","year":"2025","journal-title":"J Parkinsons Dis"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:52:07Z","timestamp":1786542727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0035378726005308"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.009","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ambulatory introduction of foslevodopa\/foscarbidopa in Parkinson's disease in private practice. Case series of the first 22 patients","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}